病例赛沃替尼 + 奥希替尼有效克服 MET 扩增耐药，为晚期肺癌患者带来长生存希望

导语：双靶联合，破局 EGFR-TKI 耐药后继发 MET 扩增 NSCLC 治疗难题。

内容策划：nyh

项目审核：杨静

参考文献：

[1]中华医学会病理学分会, 国家病理质控中心, 中华医学会肿瘤学分会肺癌学组, 等. 非小细胞肺癌 MET 临床检测中国专家共识[J]. 中华病理学杂志, 2022, 51(11): 1094-1103.

[2]Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019 Oct;121(9):725-737.

[3]Arteaga CL. HER3 and mutant EGFR meet MET. Nat Med. 2007 Jun;13(6):675-7.

[4]Wang Q, Yang S, Wang K, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol. 2019 Jun 21;12(1):63.

[5]Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023 Jan 9;13(1):98-113.

[6]Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 Mar;21(3):373-386.

[7]Ahn MJ, et al. MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib. 2023 WCLC EP08.02-140.